Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 2/20 | 0.42 |
| ▸ | NMT1 | P30419 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353450 | 0.75 | — | — | |
| SCHEMBL928758 | 0.75 | KDM4E (0.45) | DPP4KDM4EMAPTKMT2A | |
| SCHEMBL2108784 | 0.74 | CYP11B1 (0.43) | DPP4HSD11B1KDM4EMAPTHPGD | |
| Hydrochloric Acid SCHEMBL4537543 | 0.74 | DPP4 (0.49) | DPP4PNMTKDM4EKMT2A | |
| SCHEMBL2491544 | 0.73 | DPP4 (0.47) | DPP4PNMTKDM4EMAPT | |
| SCHEMBL30580351 | 0.72 | DPP4 (0.42) | DPP4PNMTKDM4EMAPTKMT2A | |
| SCHEMBL17778287 | 0.69 | DPP4 (0.40) | DPP4KDM4EMAPT | |
| SCHEMBL15382408 | 0.69 | DPP4 (0.40) | DPP4PNMTKDM4EMAPT | |
| SCHEMBL11094401 | 0.69 | L3MBTL1 (0.50) | DPP4KDM4EMAPTKMT2A | |
| SCHEMBL13793929 | 0.68 | FABP4 (0.48) | HSD11B1IDO1MAPTHPGDFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912986-B1 | IMIDIAZO -AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8158648-B2 | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | LI JAMES J (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158648-B2 | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | LI JAMES J (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158648-B2 | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | LI JAMES J (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-7572807-B2 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572807-B2 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572807-B2 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1912986-A1 | IMIDIAZO -AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | Brystol-Myers Squibb Company (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006135667-A1 | IMIDIAZO -AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281750-A1 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | DPP4 1392/4885PNMT 3300/4885NMT1 467/4885 |
| US-20060281750-A1 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | HSD11B1, HSD17B1, HSD11B2 | DPP4 1353/4885PNMT 3180/4885NMT1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.